QyPredict®

About Qynapse

Founded in 2014 and headquartered in Paris, Qynapse operates at the intersection of neuroscience, AI, and digital health. The company has developed a regulatory-cleared (FDA, CE) software platform, QyScore®, which analyzes brain MRI scans to produce precise volumetric and white matter integrity measures, addressing a critical need for objective diagnostics in neurodegenerative diseases. With a focus on reducing misdiagnosis rates and improving patient outcomes, Qynapse targets both clinical care and pharmaceutical R&D, positioning itself as a key enabler in the precision medicine landscape for CNS disorders. Its technology is validated against gold-standard manual segmentation and leverages a large normative dataset.

Therapeutic Areas